glp-1 approved for type 1 diabetes The role of GLP1 receptor agonists in adult-onset mellitus GLP-1 Drugs and Type 1

Pouchon A, Vinckier F, Dond C, Gueguen MC, Polosan M, Bastin J

The SURPASS-CVOT trial (NCT04255433) will assess the cardiovascular safety of tirzepatide compared to dulaglutide in people with T2D and established atherosclerotic disease [111]

In addition, the accumulation of acylcarnitine in the pathological state of the liver leads to insulin resistance, which further aggravates the development of liver diseases and results in a vicious cycle [211]

Epitalon melatonin-boosting effects could interact with drugs that affect melatonin metabolism

Clinical trials lasting 68 weeks and longer show that people who continue treatment are more likely to achieve and sustain meaningful weight loss compared to those who stop therapy